Pomerantz Law Firm Initiates Investigation for PetMed Express Investors Amid Concerns

Investor Alert: Pomerantz Law Firm Investigates Claims for PetMed Express, Inc.

Pomerantz LLP, a leading law firm renowned for its expertise in corporate and securities law, has announced an investigation into claims on behalf of investors of PetMed Express, Inc. (NASDAQ: PETS). This inquiry is fueled by alarming allegations concerning possible securities fraud and other questionable business practices involving the company’s management.

The issues came to light when PetMed Express, a prominent online pet pharmacy, revealed crucial delays in the release of its financial statements and reports. On June 10, 2025, the firm released a notice indicating a postponement in their fourth-quarter and year-end earnings announcement. They cited the need for additional time to finalize their year-end audit process, a move that raised suspicions among investors. Subsequently, the company's stock plummeted, falling by $0.47 per share, which equated to an 11.22% drop, closing at $3.72 per share on June 11, 2025.

The situation escalated when, on July 1, 2025, PetMed announced another delay in filing its Annual Report for fiscal 2025. This delay was part of an internal investigation focusing on revenue recognition practices. The news impacted investor confidence, further driving down the stock price by $0.05 per share, culminating in a closing price of $3.27 per share.

PetMed's troubles didn't cease; on November 12, 2025, the company declared its inability to file its quarterly report promptly, claiming it needed more time to complete the quarterly report for the previous period, which was hindered by the ongoing investigation by the Audit Committee. This revelation led to a dramatic drop in share price, with a staggering 32.41% decline to $1.96 per share on November 13, 2025.

The ongoing investigations raise pertinent questions: Can PetMed Express recover from this crisis? How deep does the alleged fraud go? These inquiries and more reflect the pressing concerns confronting affected investors.

The Pomerantz Law Firm, with its impressive history in defending investors' rights, particularly in cases of securities fraud and breaches of fiduciary duties, aims to bring to light all relevant facts surrounding these allegations. Established by Abraham L. Pomerantz, whose legacy in class action cases remains unmatched, the firm has successfully secured substantial damages on behalf of investors repeatedly through its history.

For individuals affected by PetMed’s price drops or any alleged misconduct, the Pomerantz firm encourages them to reach out for potential class action participation. Anyone with relevant information or claims against the company can contact attorney Danielle Peyton directly at [email protected] or by calling 646-581-9980, ext. 7980.

Pomerantz's focus is not just on recovering losses but also on ensuring that corporate accountability is enforced. As the investigation unfolds, it highlights a crucial moment for PetMed and its investors, reflecting the larger themes of trust and transparency within corporate practices. In a landscape marred by uncertainties, the implications of this case could resonate far beyond the immediate financial repercussions. The findings of this investigation may set precedents for future practices in not just PetMed, but the broader industry as well.

Thus, the unfolding situation at PetMed Express serves as a reminder to investors of the significance of due diligence and the potential risks associated with corporate investment. It's an unfortunate yet potent lesson on the importance of corporate governance and ethical business practices, underscoring a collective responsibility to uphold integrity in the financial markets.